Medicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients
The Medicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients, making the United Kingdom the first country to approve the world's first COVID-19 antiviral oral drug.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthMedicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients
Sign in or subscribeBrowse free archive reportsThe Medicines and Healthcare products Regulatory Agency grants conditional authorisation to Merck's molnupiravir, which can be used to treat symptomatic COVID-19 patients, making the United Kingdom the first country to approve the world's first COVID-19 antiviral oral drug.